NeuroMetrix Issued New U.S. Patent for Quell Wearable Pain Relief Technology

NeuroMetrix Inc. announced that the U.S. Patent and Trademark Office has issued the company a patent covering key technology to enable the safe delivery of Quell therapy for chronic pain while the user is sleeping. More than 80 percent of chronic pain sufferers report low quality sleep, which then further exacerbates pain. Quell is the only high intensity transcutaneous electrical nerve stimulator cleared by the U.S. Food and Drug Administration (FDA) for use while sleeping.
 
The claims cover a novel approach to using skin-electrode impedance measurements to continually monitor the Quell electrode array contact area. If the area drops to a critical level due to unintended electrode peeling, the device automatically shuts off electrical stimulation thereby providing a safety mechanism while the user is sleeping and unaware.
 
This patent further establishes and differentiates the leading technology and clinical benefits of Quell Wearable Pain Relief Technology.
 
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81 percent of Quell users reported an improvement in their chronic pain. Quell users can start, stop, and adjust therapy discreetly via the optional Quell Relief app. Quell also offers advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers.
 
NeuroMetrix is a commercial stage healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company’s lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company is located in Waltham, Mass., and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996.